Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age and an extension phase of the 16µg/24h dose group (LCS16 arm) up to 5 years
Levonorgestrel
91665
NCT00528112
Contraception
Phase 3
 
December 2016

Powered by ideaPoint, Inc.